User:Tony Mach/inborn2
Appearance
GeneReviews: GSD IX Phosphorylase Kinase Deficiency
…
- Complex I: NADH dehydrogenase (ubiquinone)
- Complex II: Succinate dehydrogenase
- Complex III: Coenzyme Q – cytochrome c reductase
- Complex IV: Cytochrome c oxidase
- Complex V: ATP synthase
…
…
…
- de:Energiebereitstellung
- de:Steady State (Sportwissenschaft)
- de:Atmungskette
- de:ATP-Synthase
- de:Substratkettenphosphorylierung
…
The diagnosis of dermatomyositis is based on five criteria
- …
- Using a blood test, finding higher levels of enzymes found in skeletal muscle, including
- creatinine kinase
- aldolase (Carbohydrate metabolism)
- glutamate oxaloacetate (indirectly related to carbohydrate metabolism)
- pyruvate transaminases (Carbohydrate metabolism)
- lactate dehydrogenase (Carbohydrate metabolism)
- …
Galactose is metabolised almost exclusively by the liver. Galactose is also produced from lysosomal degradation of glycoproteins and glycolipids.
Glycolytic step Enzyme |
Gene: Organ(s) Disease (Synonyms) |
Reported symptoms. Forms (if applicable) Note: Not all patients have all symptoms; severity and presentation can vary. |
Diagnostic tests | Management and treatment | References and links |
---|---|---|---|---|---|
Glycolysis step 8 Phosphoglycerate mutase |
PGAM2: Muscle GSD type X (GSD 10, muscle phosphoglycerate mutase deficiency, myopathy due to PGAM deficiency, PGAMD) |
Myopathy, exercise intolerance. Exercise-induced cramps, myoglobinuria and myalgia. Rhabdomyolysis possible. Rhabdomyolysis/myoglobinuria may cause acute renal failure. |
No treatment information in references given. | NLM/GHR:PGAM2 OMIM:PGAM2 NLM/GHR:GSD X OMIM:GSD X GARD:GSD X ORPHA:GSD X | |
Glycogenolysis final step: Release of G-1-P – Phosphorylase kinase, alpha 1 (Activation of muscle glycogen phosphorylase, see GSD 5) |
PHKA1: Muscle GSD type IXd (GSD 9d, phosphorylase b kinase deficiency, PhK deficiency, muscle glycogenosis) |
Myopathy. Exercise-induced muscle weakness or stiffness. Relative mild compared to other metabolic myopathies. Typically adult-onset, some asymptomatic in late adulthood. No liver involvement. | Exercise test: Both impaired and normal lactate observed; possible submaximal/maximal or aerobic/anaerobic discrepancy. Normal or exaggerated ammonia response.[2] | NLM/GHR:PHKA1 OMIM:PHKA1 NLM/GHR:GSD 9 OMIM:GSD 9d ORPHA:GSD 9d/9e | |
Glycogenolysis step: Release of G-1-P – Glycogen phosphorylase
|
PYGM: Muscle GSD type V (GSD 5, McArdle's disease, muscle phosphorylase deficiency, myophosphorylase deficiency, PYGM deficiency) |
Myopathy: Exercise intolerance, symptoms tend to improve with rest. "Second wind" phenomenon in most. Rhabdomyolysis and myoglobinuria possible. Progressive muscle weakness worsens in two-thirds of affected individuals, however in some the muscle weakness is stable. Onset forms: infant, child, adult. Infant-form most severe (e.g. progressive respiratory failure), adult-onset can be very mild (e.g. mainly poor stamina). |
Exercise test: Severely impaired rise of lactate. Normal or enhanced ammonia.[3][4] | NLM/GHR:PYGM OMIM:PYGM NLM/GHR:GSD 5 OMIM:GSD 5 GARD:GSD 5 ORPHA:GSD 5 | |
Glycolysis step 3 Phosphofructo-kinase 1 (Not involved in glyconeogenesis) |
PFKM: Muscle, also RBCs GSD type VII (GSD 7, Tarui's Disease, Phosphofructokinase deficiency) |
Late-onset form': Presents later in life. Myopathy, weakness and fatigue. Exercise intolerance (more than in GSD 5). Severe symptoms from classic type are absent. | Exercise test: Late about 3 times increase of lactate (higher than in GSD 5 and lower than in healthy). Increased rise of ammonia.[4] | No specific treatment. General advise is avoidance of vigorous exercise and of high-carbohydrate meals. | NLM/GHR:PFKM OMIM:PFKM OMIM:PFKL NLM/GHR:GSD VII OMIM:GSD VII GARD:GSD VII ORPHA:GSD VII |
Glycolysis step 9 Enolase 3 (Beta-enolase, β-enolase) |
ENO3: Muscle GSD type XIII (GSD 13, β-enolase deficiency, beta-enolase deficiency, enolase 3 deficiency, muscle enolase deficiency) |
Myopathy. Exercise-induced myalgias, generalized muscle weakness and fatigability. | Exercise test: No rise of lactate. Biopsy: Focal sarcoplasmic accumulation of glycogen-beta particles. Immunohistochemistry and immunoblotting show reduced beta-enolase protein. |
No treatment information in references given. | NLM/GHR:ENO3 OMIM:ENO3 OMIM:GSD XIII GARD:GSD XIII ORPHA:GSD XIII
|
Glycolytic step Enzyme |
Gene: Organ(s) Disease (Synonyms) |
Reported symptoms. Forms (if applicable) Note: Not all patients have all symptoms; severity and presentation can vary. |
Diagnostic tests | Management and treatment | References and links |
---|---|---|---|---|---|
Inter-conversion of pyruvate and lactate. – Lactate dehydrogenase A
|
LDHA: Muscle GSD type XI (GSD 11, lactate dehydrogenase deficiency, LDH deficiency) |
Myopathy. Exercise intolerance. Note: Deficiency of dehydrogenase-B (LDHB) has been observed as asymptomatic. |
Exercise test: Normal rise of pyruvate, impaired rise of lactate. | No treatment information in references given. | NLM/GHR:LDHA OMIM:LDHA NLM/GHR:GSD 11 OMIM:GSD 11 ORPHA:GSD 11 ORPHA:GSD 11 |
Glycogenesis step: Glucogen chain branching – Glycogen branching enzyme
|
GBE1: Liver, muscle GSD type IV (GSD 4, Andersen's disease, amylopectinosis, brancher deficiency, glycogen branching enzyme deficiency, familial cirrhosis with deposition of abnormal glycogen) |
Adult neuromuscular form | Activity of branching enzyme in erythrocytes. | High-protein diet. Liver transplant for progressive liver disease. Cardiomyopathy may require certain medications. | NLM/GHR:GBE1 OMIM:GBE1 NLM/GHR:GSD 4 OMIM:GSD 4 GARD:GSD 4 ORPHA:GSD 4 |
Glycogenesis step: Glycogen primer synthesis – Glycogenin
|
GYG1: Muscle GSD type XV (GSD 15, glycogenin deficiency) Polyglucosan body myopathy type 2 (PGBM2) |
GSD 15: Myopathy, cardiomyopathy. Rare. Muscle weakness. PGBM2: Myopathy. Proximal muscle weakness of the lower limbs, gait disturbances. Upper limbs and/or distal muscle weakness in some. Onset-age highly variable, slowly progressive. |
Skeletal muscle biopy: deficit of glycogen, predominance of slow-twitch, oxidative muscle fibers and mitochondrial proliferation. Endomyocardial biopsy: hypertrophic cardiomyocytes, enlarged nuclei and large centrally located vacuoles containing periodic acid Schiff (PAS)-positive material (but ultrastructurally different from glycogen). Glycogen depletion in he remainder of the cytoplasm. |
No treatment information in references given. | NLM/GHR:GYG1 OMIM:GYG1 OMIM:GSD 15 ORPHA:GSD 15 OMIM:PGBM2 ORPHA:PGBM2
|
Glycolytic step Enzyme |
Gene: Organ(s) Disease (Synonyms) |
Reported symptoms. Forms (if applicable) Note: Not all patients have all symptoms; severity and presentation can vary. |
Diagnostic tests | Management and treatment | References and links |
---|---|---|---|---|---|
Glycolysis step 4 Aldolase A |
ALDOA: Muscle, also liver and RBCs GSD type XII (GSD 12, Aldolase A deficiency, ALDOA deficiency, red cell aldolase deficiency) |
Muscle Symptoms: Myopathy. Exercise intolerance, cramps. In some rhabdomyolysis and myoglobinuria. Liver Symptoms: In some Hepatomegaly RBC Symptoms: Hemolytic anemia. Rhabdomyolysis/myoglobinuria may cause acute renal failure. |
No treatment information in references given. | NLM/GHR:ALDOA OMIM:ALDOA OMIM:GSD XII GARD:GSD XII ORPHA:GSD XII | |
Glycogenesis step: Glucogen chain lengthening – Glycogen synthase
|
GYS1: Muscle GSD type 0b (GSD 0b, glycogen synthetase deficiency) |
Myopathy, cardiomyopathy, exercise intolerance. | NLM/GHR:GYS2 OMIM:GYS2 OMIM:GSD 0B ORPHA:GSD 0B | ||
Degradation of glycogen to glucose in lysosomes – Acid alpha-glucosidase (Alternative pathway to glycogenolysis) |
GAA: Myopathy GSD type II (GSD 2, Pompe's disease, acid maltase deficiency, deficiency of lysosomal alpha-glucosidase, cardiomegalia glycogenica) |
Classic infantile form (Pompe disease): Cardiomyopathy and muscular hypotonia. In some respiratory involvement. Juvenile and adult form:: Myopathy of the skeletal muscles. Some similarity to limb-girdle dystrophy. In some respiratory involvement. Non-classic infantile form: Less severe. |
NLM/GHR:GAA OMIM:GAA NLM/GHR:GSD 2 OMIM:GSD 2 GARD:GSD 2 ORPHA:GSD 2 |
- ^ Cite error: The named reference
Stryer95
was invoked but never defined (see the help page). - ^ OMIM:GSD 9d
- ^ Livingstone, Callum; Chinnery, Patrick F.; Turnbull, Douglass M. (2001). "The ischaemic lactate-ammonia test". Ann Clin Biochem. doi:10.1258/0004563011900786.
- ^ a b Piirilä, Päivi; Auranen, Mari (2016). "Unique Exercise Lactate Profile in Muscle Phosphofructokinase Deficiency (Tarui Disease); Difference Compared with McArdle Disease". Front Neurol. doi:10.3389/fneur.2016.00082.
{{cite journal}}
: CS1 maint: unflagged free DOI (link)